Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

Journal of Neuro-Oncology

Volumn 128, Issue 1, 2016, Pages 163-171

  Khasraw, Mustafa ^a,b   Lee, Adrian ^a,b   McCowatt, Sally ^a   Kerestes, Zoltan ^a   Buyse, Marc E ^c   Back, Michael ^a,b   Kichenadasse, Ganessan ^c,d   Ackland, Stephen ^e   Wheeler, Helen ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

Cilengitide; Glioblastoma; Procarbazine; Radiotherapy; Temozolomide

Indexed keywords

ALANINE AMINOTRANSFERASE; CILENGITIDE; LEVETIRACETAM; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHENYTOIN; PROCARBAZINE; STEROID; TEMOZOLOMIDE; VALPROIC ACID; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; SNAKE VENOM; TUMOR SUPPRESSOR PROTEIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ADVERSE DRUG REACTION; AGED; AGITATION; ALOPECIA; ANOREXIA; ARTICLE; ATAXIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DNA METHYLATION; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; EPILEPSY; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; INFECTION; INSOMNIA; INTRACRANIAL PRESSURE; KIDNEY DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METRONOMIC DRUG ADMINISTRATION; MGMT GENE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; SEIZURE; SENSORY DYSFUNCTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; VERTIGO; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; ANALOGS AND DERIVATIVES; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; TREATMENT FAILURE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROCARBAZINE; SNAKE VENOMS; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84959497239     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2094-0     Document Type: Article

References (29)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-oncology 14(suppl 5):v1–v49
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
3. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich P-Y (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712–2718
4. Hoelzinger DB, Demuth T, Berens ME (2007) Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99(21):1583–1593
5. Stupack DG (2007) The biology of integrins. Oncology (Williston Park, NY) 21(9 Suppl 3):6–12
6. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC (2008) Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18(3):378–386
7. Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I (2013) Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain 136(2):564–576
8. Smith J (2003) Cilengitide Merck. Curr Opin Investig Drugs (London, England: 2000) 4(6):741–745
9. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651–1657
10. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O’Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610–5617
11. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S (2012) A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118(22):5601–5607
12. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124(11):2719–2727
13. 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10(4):332–337
14. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 43:143–151
15. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88(7):1004–1011
16. Kurzen H, Schmitt S, Näher H, Möhler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14(7):515–522
17. Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro-oncology 11(1):69–79
18. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res 50(9):2759–2764
19. 6-alkylguanine-DNA alkyltransferase in rat tissues. Carcinogenesis 15(8):1681–1688
20. Beith J, Cook R, Robinson B, Levi J, Bell D, Wheeler H (1997) Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high grade gliomas. Proc Am Assoc Cancer Res 16:386
21. Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A (2008) Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87(2):143–151
22. Yung W, Albright R, Olson J, Fredericks R, Fink K, Prados M, Brada M, Spence A, Hohl R, Shapiro W (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588
23. Newlands E, Foster T, Zaknoen S (2003) Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 89(2):248–251
24. 6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27(8):1262–1267
25. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085–4091
26. Shibui S, Narita Y, Mizusawa J, Beppu T, Ogasawara K, Sawamura Y, Kobayashi H, Nishikawa R, Mishima K, Muragaki Y (2013) Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol 71(2):511–521
27. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann R-D, Steinbach JP, Hundsberger T, Wick W, Meyermann R et al (2006) Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24(27):4412–4417
28. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann R-D, Reifenberger G, Weller M et al (2009) Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27(8):1257–1261
29. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16(8):2443–2449